Brinzolamide
As of the edition of 20 October 2026, Brinzolamide is a small molecule: marketed, first approved in 1998 (US); acts on CA2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Azopt
- First approved
- 1 April 1998 (US)
- Approvals on record
- 13 in 7 regions
- Holder of the most recent approval
- ZENTIVA FRANCE; 8 holders in all
- Registered trials
- 43, 7 stopped early
- Disease areas
- Eye; Heart and blood vessels
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Brinzolamide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CA2 | Carbonic anhydrase 2 | P00918 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 5 | 0 | 1 |
| Phase 3 | 14 | 11 | 0 | 3 |
| Phase 4 | 20 | 15 | 1 | 3 |
| All trials | 43 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alcon | Originator and Lead sponsor of trials | 1998 to now |
| Novartis | Applicant | 1998 to now |
| Senju Pharmaceutical | Applicant | 2020 to now |
| Sandoz | Acquired holder | 2023 to now |